New: Clinical trial search, funded by the National Cancer InstituteNew: NCI-funded clinical trial search

Would you use sparsentan for secondary FSGS from Alport syndrome?

Ask a clinical question

Answers grounded in the literature and physician expertise.

Related Questions

What clinical criteria do you use to decide between antivirals, rituximab, plasmapheresis, or a combination therapy for treating hepatitis C virus-associated cryoglobulinemic membranoproliferative glomerulonephritis?

Do you think the benefits of performing a repeat kidney biopsy to assess histologic evidence of disease activity or chronic damage outweigh the risks in a patient with recently treated lupus nephritis and improving creatinine levels?

Do you perform a repeat kidney biopsy in a patient with IgA nephropathy who has achieved partial proteinuria reduction on current therapy but has not reached the target of below 1 g per day, to assess residual histologic activity before escalating treatment?

About Mednet

A community where doctors find answers to medicine's toughest questions.

Verified, credentialed physicians
45,000+ members across 23 specialties
Free CME and MOC credit

Evidence Meets Expertise

Community

Browse Specialties
Code of Conduct
AI Community Guidelines

Tools

Mednet AI
TrialMatch
Mobile App

Company

About
Careers
Events
Our Work
Blog

Support

FAQs
Contact Us
Programs

Legal

Privacy Policy
Terms of Service

© 2026 Mednet Inc. All rights reserved.